WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--
Bioanalytical Systems, Inc. (BASi) (NASDAQ: BASI), a recognized
global leader in the development of instrumentation for automated blood
sampling in animal models, is proud to announce its launch of the
Embrace Automation grant program featuring the BASi Culex NxT ™
Automated Blood Sampling system and Raturn™.
As laboratory techniques and instrumentation evolved, many formerly
manual processes became automated—from basic pipetting to intricate
high-throughput screening. In vivo studies are no different. BASi Culex®
Automated Blood Sampling systems deliver programmable, continuous
automated blood micro sampling, thus providing a full pharmacokinetic
curve from a single, fully conscious, freely moving animal. The system
allows for the simultaneous collection of multiple data streams such as
blood, bile, metabolites, dialysates and more from species as small as
mice and as large as swine. Researchers around the globe have been
screening compounds and generating high quality data from less stressed
animal models with minimal handling by technicians using the BASi Culex®
system and accessories for nearly two decades. However, many researchers
still labor through in vivo drug discovery studies manually and now have
the opportunity to experience an automated platform at no cost for a
thirty-day period.
With BASi's Embrace Automation grant program, researchers are provided
with a BASi Culex NxT ABC-R™, four catheterized animals, consumables to
run studies, and full training and support for the instruments.
Jacqueline Lemke, President and Chief Executive Officer of BASi,
commented, "BASi is proud to launch this exciting Embrace Automation
Culex® grant program. We know that the in vivo sampling systems provide
better data with less stressed animals, save time and create
efficiencies by using fewer animal models and less technician time when
running pharmacokinetic and pharmacodynamic studies. This program gives
our customers a free trial to see first-hand the benefits of automated
sampling. Feedback received from customers in the program thus far has
been very positive and often resulted in conversion to automation. BASi
has multiple large pharmaceutical companies and academic research
facilities globally enjoying the benefits of our technology. With the
BASi Embrace Automation Program, we want to give all researchers a
chance to experience the innovation that they need to generate better
data, using less animals and at lower costs than the still highly used
manual techniques. Better data, saving lives, saving time and saving
money is the BASi Culex® difference."
For more information on how to get your laboratory enrolled in our
Embrace Automation grant program, please contact Gloria Holbrook, BASi
Culex® Product Development Manager, at 765-237-7796, or Shelly Carballo,
BASi Business Development, at 765-418-4384. You can also visit www.basinc.com/products/embrace
for program information.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug
development companies and medical research organizations. BASi is
recognized globally for expertise in automated blood sampling
instruments has been manufacturing these instruments and accessories for
over 40 years. BASi focuses on developing innovative products that
increase efficiency and reduce the cost of taking new drugs to market.
Visit www.BASinc.com
for more information about BASi.
This release may contain forward-looking statements that are subject
to risks and uncertainties including, but not limited to, risks and
uncertainties related to changes in the market and demand for our
products and services, the development, marketing and sales of products
and services, changes in technology, industry standards and regulatory
standards, and various market and operating risks detailed in the
company's filings with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160825005574/en/
